$ZBIO News

Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32

Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target

Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related Disease

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Zenas BioPharma Announces That Safety And Efficacy Outcomes From The Phase 3 INDIGO Trial Will Be Presented At The European Alliance Of Associations For Rheumatology Congress, June 3-6

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22

Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF Inhibitor

Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) Estimate

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026